Ticker: INDP

Indaptus Therapeutics, Inc. (NASDAQ: INDP) - Quick take Short summary: the company is a clinical‑stage biotech advancing its lead candidate Decoy20. Financially it's burning cash while raising capital through a SEPA, private placements and convertible notes; management completed a reverse split a...